Non-invasive measurement of brain glucose metabolism using PET scans

Investigating the Effect of Glucagon on Cognitive Function and Cerebral Glucose Metabolism in Humans: A Pilot study_A

This study is testing a new way to measure how the brain uses sugar by using PET scans instead of blood tests in healthy adults aged 25 to 70.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 6 (estimated)
• Ages: 25 Years to 70 Years
• Sex: All
• Sponsor: University of Copenhagen (Academic / other)
• Locations: 1 site (Copenhagen)
• Trial ID: NCT06647368 on ClinicalTrials.gov

What this trial studies

This study aims to develop a non-invasive method for quantifying cerebral glucose metabolism using PET scans in humans. It will compare traditional arterial blood sampling methods with image-derived measurements to see if they correlate. Healthy participants aged 25 to 70 will undergo a series of scans and blood sampling after fasting, involving the administration of radioactively labeled glucose. The goal is to simplify the research setup for future studies on the effects of glucagon on cerebral glucose metabolism.

Who should consider this trial

Good fit: Ideal candidates for this study are healthy adults aged 25 to 70 with a body mass index of 25 kg/m² or less.

Not a fit: Patients with diabetes, psychiatric disorders, or significant cardiac problems may not benefit from this study.

Why it matters

Potential benefit: If successful, this method could provide a simpler and safer way to study brain glucose metabolism, potentially leading to better understanding and treatment of related conditions.

How similar studies have performed: While the approach of using image-derived measurements is innovative, similar studies have shown promise in non-invasive imaging techniques.

Eligibility criteria

Inclusion Criteria:

* Capable of understanding the participant information and signing the consent form
* Between 25 and 70 years of age
* Body mass index \<= 25 kg/m\^2

Exclusion Criteria:

* Enrolment in other research project that might interfere with the study
* Diabetes diagnosis
* Pregnancy or breastfeeding
* Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol
* Diagnosis of psychiatric disorders, dementias, or any other neurological disorders that in the opinion of the investigator precludes compliance with the study protocol, evaluation of the results or represents an unacceptable risk for the participants safety
* Severe claustrophobia
* Cardiac problems including any of the following:

  1. Classified as being in New York Heart Association (NYHA) class III or IV
  2. Angina pectoris (chest pain) within the last 6 months
  3. Acute myocardial infarction (heart attack) within last 2 years
* Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic.
* Active or recent malignant disease
* Current or history of severe alcohol use or drug/chemical abuse as per investigator's judgement
* Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol

Where this trial is running

Copenhagen

• Department of Physiology and Nuclear Medicine, University of Copenhagen - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark — Copenhagen, Denmark (Recruiting)

Study contacts

• Principal investigator: Nicolai J Wewer Albrecthsen, MD PhD — Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
• Study coordinator: Nina L Hansen, MD

Conditions Cerebral Glucose Metabolism